HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Concept Chemicals warning letter

This article was originally published in The Rose Sheet

Executive Summary

Concept Chemicals warning letter: FDA tells Houston-based company June 11 that cloroxylenol-containing JOVAE Bio-Intensive Shampoo is an unapproved new drug due to label claims for "relief of dry, itchy, flaky scalp" problems caused by "dandruff, psoriasis and seborrheic dermatitis" and "antimicrobial" benefits. The claims make JOVAE subject to the 1991 final rule for dandruff products, under which cloroxylenol is not approved, FDA explains. JOVAE also is misbranded because it does not carry appropriate label warnings and directions, the agency notes. In addition, FDA states, the products are adulterated due to current Good Manufacturing Practices violations. Concept Chemicals, which distributes the shampoo to salons in Houston and surrounding areas, says it is talking to FDA and expects only minor changes in product labeling...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel